For U.S. IPOs, 2017 has been the year of the flop. Blue Apron has tanked since it started trading last month. Shares of Snap fetch less than $15, the lowest since its debut in March. And the Bloomberg U.S. IPO index has risen just 1.5 percent this year, underperforming the S&P; 500's 10 percent gain. What's going on? Bloomberg IPO reporter Alex Barinka joins host Alex Sherman to explain the lackluster performance of Blue Apron and Snap, and how MuleSoft and Canada Goose have avoided the same fate.  See omnystudio.com/listener for privacy information.

For U.S. IPOs, It's the Year of the Flop

Bloomberg M&A reporters, joined by outside experts and members of Bloomberg's Deals team, examines the week's biggest deals and highlights M&A trends most under scrutiny by Wall Street. He'll talk to reporters who broke Bloomberg's major scoops and interview investors, executives, lawyers and bankers for an inside peek into what's going on inside corporate boardrooms and what it's like working with the world's largest companies and richest people.

Business

Investing

Careers

Management & Marketing

Business News

Shopping

News

A few decades ago, nobody really questioned vaccines. They were viewed as a standard part of staying healthy and safe. Today, the number of people questioning vaccines risks prolonging a pandemic that has already killed hundreds of thousands of Americans. How we got to this moment didn’t start with the rollout of vaccines or in March 2020, or even with the election of Donald Trump. Our confidence in vaccines, often isn't even about vaccines. It’s about trust. And that trust has been eroding for a long time. Doubt, a new series from Bloomberg’s Prognosis podcast, looks at the forces that have been breaking down that trust. We'll trace the rise of vaccine skepticism in America to show how we got here — and where we’re going. Doubt launches on March 23. Subscribe to Prognosis today on Apple Podcasts, Spotify or wherever you get your podcasts. See omnystudio.com/listener for privacy information.

Introducing: Doubt

The killers of Berta Caceres had every reason to believe they’d get away with murder. More than 100 other environmental activists in Honduras had been killed in the previous five years, yet almost no one had been punished for the crimes. Bloomberg’s Blood River follows a four-year quest to find her killers – a twisting trail that leads into the country’s circles of power. Blood River is out now. See omnystudio.com/listener for privacy information.

Introducing: Blood River

On this new show from Bloomberg, hosts Mike Regan and Sarah Ponczek speak with expert guests each week about the main themes influencing global markets. They explore everything from stocks to bonds to currencies and commodities, and how each asset class affects trading in the others. Whether you’re a financial professional or just a curious retirement saver, What Goes Up keeps you apprised of the latest buzz on Wall Street and what the wildest movements in markets will mean for your investments.  See omnystudio.com/listener for privacy information.

Introducing "What Goes Up," A New Show From Bloomberg

On this new show from Bloomberg, hosts Francesca Levy and Rebecca Greenfield navigate the productivity industry by way of their own experiences. In each episode, one of the two becomes a human guinea pig as she tries to solve a specific work-related problem. Using the advice of so-called productivity experts, the duo tackles obstacles like ineffective to-do lists, overflowing inboxes and unruly meetings. Follow along with their attempts, insights and missteps, and maybe find a solution that will work for you.  See omnystudio.com/listener for privacy information.

Introducing "Works For Me," A New Podcast From Bloomberg

In the final episode of Deal of the Week, Ed Hammond is joined by Bloomberg Gadfly columnist Brooke Sutherland and Ian King to talk about the fallout from the US government’s unexpected decision to review Broadcom’s attempted takeover of rival semiconductor maker Qualcomm on national security grounds. The trio discuss the contrasting cultures of the two tech giants and ask the question of which company is more likely to keep the US at the forefront of the 5G revolution. Finally, they try to predict how Qualcomm’s shareholders are likely to vote if the Committee of Foreign Investment in the United States ever gives them the chance. See omnystudio.com/listener for privacy information.

For U.S. IPOs, It's the Year of the Flop

Download our free app to listen on your phone